Understanding the Diverse Strains of Coronavirus and Their Impact
Written on
Chapter 1: Overview of SARS-CoV-2 Variants
Recent research into the SARS-CoV-2 virus has unveiled a multitude of strains, but only a select few are of major concern. A pivotal study published in July 2024 in Frontiers of Microbiology, titled “Geographic and Genomic Distribution of SARS-CoV-2 Mutations,” stands out for its extensive bioinformatics analysis. This study evaluated 48,635 SARS-CoV-2 genomes from laboratories around the globe, identifying a staggering 353,341 mutational events. The researchers noted, "Our analysis…confirms a low mutation rate of the virus, with an average of 7.23 mutations per sample compared to the reference SARS-CoV-2 genome sequences."
The dominant mutation identified was D614G, where the amino acid at position 614 transitioned from D (aspartic acid) to G (glycine), leading to the emergence of the G614 variant. Subsequent studies corroborate that G614 accounts for approximately 75.7% of all SARS-CoV-2 strains circulating globally as of July. For further insights into the implications of the D614G mutation for the pandemic, please refer to the following video:
Chapter 2: Distinction Between Variants and Strains
This section delves into the various strains and variants of SARS-CoV-2. Variants are defined as any genetic mutations that differentiate one virus's genome from another. However, not all mutations result in significant biological changes. To be classified as a strain, a variant must exhibit differences at both the genomic and functional levels, such as the G614 strain.
Prof. Jonathan P. Stoye, a virologist at the Francis Crick Institute, elaborated, “A mutation signifies a change in the genetic sequence. While the occurrence of a mutational change is noteworthy, the functional ramifications are paramount.” He emphasized that only a minority of mutations confer advantages; most are neutral or detrimental to the virus's survival.
Section 2.1: The 68 Identified Strains
Only a single study published in Cell in July has comprehensively explored the functionality of various SARS-CoV-2 variants. Researchers at the China World Health Organization (WHO) Collaborating Center identified 106 mutations likely to induce functional changes. They synthesized these variants to assess their infectivity in human cells and their response to monoclonal antibodies and convalescent sera.
The study found that the D614G mutation enhances infectivity but does not appear to confer resistance to neutralizing antibodies. In their molecular analysis compared to the original Wuhan strain, 68 variants exhibited altered biological characteristics. The findings revealed:
- 24 variants with decreased infectivity, showing a reduction of 4 to 100 times, with two variants experiencing over a 100-fold decrease.
- 8 variants with increased infectivity, including the D614G mutation, while the others carried additional mutations alongside D614G.
- Variants displayed varying sensitivity to neutralization by monoclonal antibodies and convalescent sera.
Section 2.2: Real-world Implications of Findings
Encouragingly, all identified variants constitute less than 1% of circulating SARS-CoV-2 strains, with the D614G mutation being the exception, representing over 70% prevalence. The study authors noted, "D614G is particularly significant." However, they cautioned that RNA viruses frequently mutate, and while some variants may appear transiently, others could emerge unexpectedly. Continuous monitoring of circulating strains is essential.
Despite the D614G mutation's increased infectivity, it does not seem to enhance resistance to the immune system's monoclonal antibodies. The researchers found that this dominant G614 strain could infect four tested cell lines at rates 10 times higher than the original Wuhan strain. However, a limitation of the study is that the cell types used were not from the respiratory tract but rather from the liver and kidney, which may not accurately represent the virus's behavior in human lungs.
Chapter 3: Conclusion on SARS-CoV-2 Mutations
In total, at least 353,341 mutational events have been documented within SARS-CoV-2 genomes. However, only mutations that alter the virus's biological properties can be classified as strains; the rest are merely variants. Researchers synthesized 106 variants predicted to modify the virus biologically, revealing that 68 had changed infectivity and immunogenicity. Notably, aside from the D614G mutation, which has over 70% prevalence, the other strains represent less than 1% of circulating SARS-CoV-2.
As we advance, it remains uncertain if these laboratory findings accurately reflect real-world human-to-human transmission. Thus, among the 68 characterized strains, the G614 strain emerges as the most clinically relevant, while others may diminish over time, similar to the milder ?382 strain that eventually disappeared.